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The novel coronavirus outbreak of SARS-CoV-2, as of May 14, 2020, has resulted in more than 4,300,000 individuals infected and over 290,000 deaths worldwide ([@bib15]). The current pandemic, as well as the potential of future pandemics based on estimates of undiscovered zoonotic infections ([@bib9]), has brought to the forefront urgency and necessity for rapid development of pandemic countermeasures. Two countermeasures with promise for controlling the current SARS-CoV-2 pandemic are recombinant neutralizing antibodies ([@bib28], [@bib64]) and vaccines ([@bib20], [@bib22], [@bib21]) directed against the virus that causes COVID-19, SARS-CoV-2. In particular, over the past 15 years, the NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) program ([@bib7], [@bib23]), the NIH Vaccine Research Center ([@bib33]) as well as others, and, for the past three years, the DARPA Pandemic Prevention Program (P3) program ([@bib8], [@bib14], [@bib32]) have worked to define the platforms and enable technology for HIV vaccine development and rapid response to viral pandemics. Although an HIV vaccine has not yet been developed, much of the technology the HIV vaccine field has developed is now being used to fight the COVID-19 pandemic. From the HIV field and the DARPA preparedness programs have come teams and technologies that are now responding to the COVID-19 epidemic to both isolate SARS-CoV-2 neutralizing antibodies and develop SARS-CoV-2 vaccine candidates. Here we comment on some of the strategies that are being used to develop antibody and vaccine countermeasures for SARS CoV-2 ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Schema of Iterative and Synergistic Approaches Being Used to Simultaneously Develop Both Vaccines and Antibody Countermeasures for SARS-CoV-2/COVID-19

*Neutralizing antibodies*. Antibodies isolated from a single B cell are called monoclonal antibodies (mAbs) and have become an effective new biologic class in our pharmacopeia with a wide-range of FDA-approved mAbs for indications such as arthritis and other inflammatory diseases, heart disease, hypercholesterolemia, osteoporosis, cancer, and infectious diseases ([@bib59]). Recombinant human or humanized monoclonal antibodies are proving to be safe, effective, and highly specific in their ability to target a pathway, process, or invading pathogen. More than 70 recombinant monoclonal antibodies have now been approved by the FDA for use in the treatment of infectious, autoimmune and inflammatory, malignant, or cardiovascular diseases ([@bib10], [@bib59]). Specifically, recombinant neutralizing antibodies for infectious diseases, such as for protection from anthrax toxin and for the prevention of respiratory syncytial virus infection ([@bib16], [@bib59]), have been approved by the FDA. Neutralizing antibodies are currently in development for prevention and/or treatment of HIV ([@bib12], [@bib17]) and pending approval for Ebola ([@bib55]).

Thus, recombinant neutralizing antibodies isolated from those infected with SARS-CoV-2 are the most rapid and readily manufacturable immune intervention for passive administration that might be developed to either prevent or treat COVID-19 disease ([@bib1], [@bib6], [@bib28], [@bib54], [@bib58]). SARS-CoV-2 antibody countermeasures will benefit from the last 20 years of antibody optimization research that has discovered point mutations in the Fc portion of antibodies that finetune antibody function and circulation half-life ([@bib56]). Such mutations have been described for the Fc region of IgG that have prolonged antibody half-life for up to 6--7 weeks ([@bib17], [@bib52], [@bib71]). Additionally, mutations are known that can increase antibody-dependent infected cell killing and antibody-dependent complement activation ([@bib26], [@bib51]). Given the ability of certain antibodies to facilitate SARS-CoV-1 virus entry via engagement of Fc receptors on host cells ([@bib27]), the introduction of mutations that inhibit Fc binding to Fc receptors could also be important for successful development of SARS-CoV-2 neutralizing antibody treatments.

Neutralizing antibodies to the spike protein receptor binding domain (RBD) protect mice from MERS, SARS-CoV-1, and SARS-CoV-2 infection ([@bib50], [@bib66], [@bib74]). Thus, neutralizing antibodies are under development as proteins or gene-delivered formulations to prevent or treat SARS-CoV-2 infection. One example of technology now brought to bear on SARS-CoV-2 countermeasure work is the strategy developed to isolate and screen for HIV neutralizing antibodies without antibody gene cloning ([@bib37]), and this technology was recently used in China to isolate the first neutralizing antibodies to SARS-CoV-2 ([@bib28]). As seen with SARS-CoV-1 and HIV, viruses resistant to a particular antibody can emerge among the circulating virus variants ([@bib11], [@bib61]). In these cases, combinations of two of more neutralizing antibodies can broaden the efficacy of neutralizing antibody prophylaxis or treatment ([@bib42], [@bib61]). Thus, large numbers of effective neutralizing antibodies are needed so that antibody cocktails can be formulated to provide optimal coverage of circulating SARS-CoV-2 isolates.

The Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Program (P3) within the Department of Defense has played a key role in funding and driving public/private development of end-to-end platforms to rapidly develop antibody countermeasures. The DARPA P3 program aims to identify and propagate viral pathogens, isolate human neutralizing antibody sequences, develop effective approaches to deliver neutralizing antibodies as nucleic acids, and develop good manufacturing practices for a final drug product to submit to the Agency for Phase I approval within 60 days of receiving an outbreak blood specimen ([@bib8], [@bib14]).

To meet this challenge, the Duke DARPA P3 program developed a "thaw and infect" permissive cell line array to rapidly grow Risk Group 2 and 3 viruses, such as SARS-CoV-2. This team also developed platform technologies for real-time virus growth monitoring, fluorescently labeling viruses, antibody focus/plaque-reduction neutralization assays, and whole virus binding assays. By using innovative and time-tested approaches from the HIV field ([@bib30], [@bib37]), the Duke P3 group developed a rapid, virus-independent, high-throughput, semi-automated Ab sequence isolation and screening pipeline in high-containment ([Figure 2](#fig2){ref-type="fig"} ). This pipeline has recently isolated a panel of H3N2 influenza neutralizing antibodies that provide protection in mouse challenge models and is now fully engaged in isolating a cocktail of neutralizing SARS-CoV-2 human monoclonal antibodies. The human angiotensin-converting enzyme 2 (ACE2) transgenic mouse ([@bib3]) will be incorporated into the pipeline as well as rhesus and cynomolgus macaque models ([@bib41], [@bib53]) as SARS-CoV-2 acquisition models to rapidly evaluate the ability of antibodies to protect from SARS-CoV-2 challenge and the possibility of antibody-induced enhancement of disease ([@bib49]). Rapid movement of potent viral neutralizing antibodies to testing in the clinic requires an alternative to typical recombinant antibody protein production. DARPA P3 performer teams and others are therefore developing gene-delivered approaches ([Figure 1](#fig1){ref-type="fig"}) for rapid cGMP-scalable manufacturing. One approach being used is modified RNA encapsulated in lipid nanoparticles (LNPs) due to its proven utility and potential for rapid manufacturing ([@bib32], [@bib48]). In pre-clinical models, protective concentrations of recombinant neutralizing antibodies have been successfully expressed from intravenously and intramuscularly delivered LNP-encapsulated mRNA, supporting this approach for use in response to a rapidly spreading pandemic ([@bib32], [@bib47]). Moreover, Crowe at al. (Vanderbilt P3 Performer Site), in collaboration with Moderna, has successfully isolated and delivered a Chikungunya neutralizing antibody by using mRNA in LNPs in a Phase 1 human study ([@bib32]). In addition to mRNA-LNP, DNA or viral vector approaches are also being rapidly developed for pandemic prevention antibody delivery ([@bib2], [@bib44]).Figure 2Accelerated Platform Technology for Rapid B Cell Screening and Isolation of Pathogen Neutralizing Antibodies Being Used to Isolate SARS-CoV-2 Antibodies

*SARS-CoV-2 vaccine development*. Vaccines are the time-honored method for establishing long-lived immune memory for controlling infectious diseases, and technologies have been developed such that vaccines can now be developed faster than in previous times ([Figure 1](#fig1){ref-type="fig"}) ([@bib20], [@bib22], [@bib21]). Over 100 companies or academic institutions are working on COVID-19 vaccines with strategies that include recombinant vectors, mRNA in lipid nanoparticles, DNA, inactivated virus, live attenuated virus, virus-like particles, and protein subunits ([@bib62], [@bib68]). Three vaccine candidates have already advanced to Phase II testing that include an mRNA vaccine encoding the viral spike protein from Moderna, an Adeno-type 5 vector vaccine expressing the S protein from CanSino Biologicals, and a chimpanzee adenovirus encoding the spike protein from the Jenner Institute in Oxford, UK. Five other vaccine candidates are also now in phase I trials including other mRNA/LNP or DNA vaccines as well as three forms of whole inactivated vaccines ([@bib68]).

As seen from this rapid movement of SARS-CoV-2 vaccine candidates into human trials, the time it takes to develop vaccines for emerging pathogens is decreasing from that in the past for traditional childhood vaccines. Recently, a DNA vaccine for the original SARS (SARS-CoV-1) was developed in 20 months, a vaccine for H5 influenza A/Indonesia/2006 in 11 months, a vaccine for H1 influenza A/California/2009 in 4 months, and a Zika virus vaccine in 3.5 months ([@bib22]). These successes have been brought about by innovative technology and approaches that have allowed for rapid identification and sequencing of new viral pathogens and new technologies for vaccine delivery ([@bib21]). For the past 15 years, the HIV vaccine field has pioneered development and use of recombinant antibody technology, advanced computational methods, novel animal models, and new vaccine delivery approaches to accelerate HIV vaccine immunogen design and development ([@bib7], [@bib12], [@bib24], [@bib23], [@bib30], [@bib34], [@bib37]). This work has deciphered the roadblocks for this most difficult-to-develop HIV vaccine ([@bib24]). It is expected that the timeline for a SARS-CoV-2 vaccine will be much faster and much easier than for HIV-1. Investigators have worked to integrate these iterative approaches for vaccine and antibody countermeasure development and applied them to a rapid response to the COVID-19 disease epidemic caused by SARS-CoV-2 ([Figure 1](#fig1){ref-type="fig"}).

The COVID-19 pandemic caused by SARS-CoV-2 was first widely recognized in December 2019, and the first virus sequence published online in January 2020. By March 16, 2020, the first mRNA/LNP vaccine trial developed by the VRC in collaboration with Moderna had begun ([@bib45]). A rapid SARS-CoV2 vaccine development approach involves the integration of computational and structural-based immunogen design strategies; production of immunogens as inactivated virus; DNA, mRNA, vectored or protein subunits; and immunogenic profiling in animal models prior to vaccine manufacturing and testing in clinical trials ([Figure 1](#fig1){ref-type="fig"}). Computational biology techniques have facilitated the rapid analysis of antibody and virus sequences for influenza, HIV, and now SARS-CoV-2 to enable vaccine development ([@bib18], [@bib39], [@bib57], [@bib69]). Monitoring of HIV evolution by using the Los Alamos HIV Sequence Database ([@bib39]) has been critical for HIV vaccine immunogen designs. The SARS-CoV-2 virus is evolving, albeit at a slower rate than HIV, and virus evolution is a concern for successful COVID-19 vaccine development. The SARS-CoV-2 spike protein RBD is the prime target for vaccine-induced neutralizing antibodies although other spike protein neutralizing epitopes are of interest. However, comparison of the SARS-CoV2 RBD with that of SARS-COV-1 reveals only partial homology although both retain the ability to bind to the ACE2 as a receptor ([@bib70]). The GISAID database is proving to be helpful information for monitoring the viral evolution of SARS-CoV-2 ([@bib18]), and the Los Alamos National Laboratory is developing a website with tools for analysis of global SARS-CoV-2 spike protein sequences ([@bib31], [@bib40]).

Structural determination of the primary targets of neutralizing antibodies, for example, hemagglutinin in influenza, Env in HIV, and now the spike protein in SARS-CoV-2, has provided valuable atomic-level insight for vaccine design strategies. In particular, cryo-electron microscopy has enabled the rapid solution of the structure of the SARS-CoV-2 spike protein ([@bib65], [@bib70]). Structural biology analysis of pathogens combines structural, computational, biophysical, and biochemical methods to understand interactions of pathogens with the immune system ([@bib25], [@bib35], [@bib43], [@bib57]). Early this year, structural biologists pivoted to apply technology developed for HIV-1 envelope or respiratory syncytial virus (RSV) structural biology to fast-track structure-based vaccine design for COVID-19 ([@bib36], [@bib65], [@bib70], [@bib72]). Currently, established pipelines for high-resolution cryo-EM structural determination of the SARS-CoV-2 spike are integrated with the computational teams, thus providing atomic-level feedback to COVID-19 vaccine designs.

The past eight years of HIV-1 antibody discovery has provided templates for HIV-1 vaccine design aiming to elicit broadly reactive neutralizing antibodies ([@bib34], [@bib60]). From the study of the ontogeny of HIV neutralizing antibodies it has become clear that an effective vaccine will likely require multiple immunogens administered in a specific order to facilitate proper antibody development to multiple neutralizing targets on HIV ([@bib24]). Hopefully, the development of SARS-CoV-2 neutralizing antibodies will require a much simpler vaccination regimen like the Zika vaccine, where one immunization with one immunogen was sufficient to elicit protective neutralizing antibodies ([@bib46]). Such a vaccine would be amenable to rapid development, large-scale manufacturing, and global administration.

What will follow rapidly now for prevention of COVID-19 will be a number of mRNA/LNP (e.g., from Moderna/NIAID, BioNTech/Fosum, Pharma/Pfizer) or DNA (e.g., Inovio) vaccines as well as attenuated viruses, proteins, nanoparticles, and viral vectors containing SARS-CoV-2 viral genes as vaccine candidates moving through safety and immunogenicity trials, and a smaller subset of vaccine candidates will be tested in Phase III or efficacy trials to continue to determine if they are safe, as well to determine their efficacy. In parallel now with Phase I and II trials, it is important to develop capacity for large-scale vaccine production, in the event of a successful efficacy trial ([@bib13], [@bib20]). It is possible that genetic immunization strategies such as DNA or mRNA in LNPs can be manufactured more rapidly than proteins or viral vectors and can be more cost effective.

In addition to efficacy being the primary goal of SARS-CoV-2 vaccine development, safety is also a major concern ([@bib49]). Immunization with a SARS-CoV-1 vaccine has induced vaccine-associated immunopathology in the lung ([@bib5], [@bib38], [@bib63]). Both CD4 and CD8 T cell responses have been suggested to also be protective for SARS-CoV-1 ([@bib73]). Thus, careful animal preclinical studies as well as intense monitoring of human clinical trials will be of critical importance to developing safe and effective anti-COVID-19 antibody and vaccine countermeasures.

Finally, collaboration and coordination will be essential to ending the pandemic. Globally, one example of private support for COVID-19 research is the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI is raising funds for COVID-19 vaccine development and as well is funding vaccine development projects ([@bib19]). The Bill & Melinda Gates Foundation has made a \$250 million commitment to fight COVID-19 and has established a Coronavirus Immunotherapy Consortium, or CoVIC, to foster sharing and comparison of SARS-CoV-2 antibodies to speed therapeutic antibody development ([@bib4]). The recent formation of an NIH-organized public-private partnership, termed Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) ([@bib13], [@bib29]), is necessary and will facilitate a coordinated COVID-19 pandemic response. Globally, the World Health Organization is playing a critical multinational coordination and informational role ([@bib67]).
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-------

Government-funded and private initiatives have synergized to provide countermeasure platforms to rapidly respond to the SARS-CoV-2 pandemic. Continued cooperation among public and private institutions coupled with speed of development of antibody countermeasures and vaccines, with rapid evaluation of their safety and efficacy, and early planning for scale-up and manufacture will be critical for expeditious control of the global COVID-19 pandemic.
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